|
Outcomes for survivors |
|||
| Azithromycin Group (n = 14) |
Placebo Group (n = 12) |
p-value |
|
|
|
|||
| Incidence of BPD-no. (%) |
9 (64.3) |
10 (83.3) |
0.26 |
| Duration of Mechanical Ventilation-median (range) |
13 (1–47) |
35 (1–112) |
0.02 |
| Postnatal-steroid |
3 (18.8) |
8 (66.7) |
0.02 |
| Days of CPAP (range) |
8 ± 7 |
8 ± 6 |
0.98 |
| Grade III or IV IVH-no. (%) |
2 (14) |
2 (16) |
0.86 |
| PVL on HUS-no. (%) |
1 (7) |
2 (16) |
0.58 |
| Abnormal Transaminases (AST) |
0 |
1 (8) |
0.46 |
| Bilirubin Peak |
6.9 ± 1.8 |
6.4 ± 2.1 |
0.54 |
| Days to full feeds‡ |
17 ± 5 |
18 ± 4 |
0.76 |
| Feeding intolerance*-no. (%) |
4 (29) |
7 (58) |
0.12 |
| Necrotizing Enterocolitis-no. (%) |
0 |
1 (8) |
0.46 |
| Abnormal hearing screen-no. (%) |
0 |
3 (25) |
0.08 |
| Bacterial Infection: |
|||
| Blood-no. (%) |
8 (57) |
5 (42) |
0.43 |
| Urine-no. (%) |
0 |
3 (25) |
0.08 |
| CSF-no. (%) |
0 |
2 (17) |
0.20 |
| Fungal Infection: |
|||
| Blood-no. (%) |
2 (14) |
1 (8) |
1.0 |
| Urine-no. (%) |
0 |
1 (8) |
0.46 |
| CSF-no. (%) |
1 (7) |
0 |
1.0 |
| Days of Antibiotics§ |
12 ± 11 |
24 ± 23 |
0.09 |
| Caffeine Therapy-no. (%) |
13 (92) |
10 (83) |
0.58 |
| PDA†-no. (%) |
7 (50) |
9 (75.0) |
0.18 |
| Indomethacin¥ |
|||
| Median |
1 |
1 |
0.48 |
| Interquartile range |
0–1 |
0–2 |
|
| PDA ligated-no. (%) |
3 (21) |
3 (25) |
0.82 |
| Diuretics-no. (%) |
5 (35) |
7 (58) |
0.24 |
| Days of Diuretics |
12 ± 25 |
28 ± 42 |
0.23 |
| Bronchodilators-no. (%) |
4 (28) |
8 (67) |
0.05 |
| Days of Bronchodilators |
7 ± 15 |
24 ± 25 |
0.04 |
| Hospital days |
77 ± 15 |
101 ± 32 |
0.02 |
|
All data analysis was performed using ANOVA (mean ± sd), except for apgar scores and days of mechanical ventilation, which analyzed using median test. *Defined as feeds being held for more than 24 hours, while on study. †Confirmed by echocardiogram. ‡Defined as when TPN was discontinued. §Excluding azithromycin. ¥Performed using wilcoxon rank sum test. | |||
Ballard et al. Respiratory Research 2007 8:41 doi:10.1186/1465-9921-8-41 |
|||